Amlodipine better than atenolol in hypertension. More efficient prevention of the mortality and cardiovascular events according to the ASCOT trial
Nilsson, P.M.; Håkansson, J.
Lakartidningen 102(41): 2922-2923
2005
ISSN/ISBN: 0023-7205 PMID: 16294509 Document Number: 594604
Document emailed within 1 workday
Related Documents
Rocha, E.; Mello e Silva, A.; Nogueira, P. 2003: Relation between hypertension and cardiovascular events--implications for coronary prevention Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia 22(10): 1215-1224Millard, P.S. 2003: Do irbesartan and amlodipine reduce cardiovascular events in diabetic patients? Journal of Family Practice 52(8): 593-594
Guo, Y.F. 2019: Effects of aspirin on primary prevention of cardiovascular events in patients with hypertension Zhonghua Nei Ke Za Zhi 58(4): 249-251
Chen, Y.; Wang, J.; An, Y.; Gong, Q.; He, Y.; Zhang, B.; Li, H.; Shuai, Y.; Tang, X.; Jiang, Y.; Hong, J.; Yang, W.; Hu, Y.; Li, G. 2015: Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre-diabetic patients:long-term follow-up of Da Qing Diabetes Prevention Study Zhonghua Nei Ke Za Zhi 54(1): 13-17
Reis, S.E.; Feldman, A.H. 1997: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery New England Journal of Medicine 336(20): 1453; Author Reply 1453-1454
Clamp, M.; Holmes, B.; Wilcox, R. 1990: Comparative trial of nifedipine retard and atenolol in the treatment of elderly patients with mild to moderate hypertension Journal of Human Hypertension 4(5): 557-563
Helgeland, A.; Strømmen, R.; Hagelund, C.H.; Tretli, S. 1987: Enalapril, atenolol and hydrochlorothiazide in mild or moderate hypertension. A comparative multicenter trial in general practice in Norway Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 107(33): 2937-40 2968
Edwards, K.G.; Tweed, J.A.; Saul, P.A.; Wright, F.W. 1986: A comparative study of atenolol/nifedipine and atenolol/diuretic in hypertension Pharmatherapeutica 4(10): 637-641
Hiatt, W.R. 2008: Aspirin for prevention of cardiovascular events Bmj 337: A1806
Fichet, Jérôme.; Bressolle, C. 2009: Telmisartan for prevention of cardiovascular events New England Journal of Medicine 360(3): 302-303; Author Reply 303
Nossent, H. 2000: Risk of cardiovascular events and effect on mortality in patients with rheumatoid arthritis Journal of Rheumatology 27(9): 2282-2283
Oganov, R.G.; Gratsianskiĭ, N.A.; Mazur, N.A.; Lazebnik, L.B.; Belousov, I.B.; Sidorenko, B.A.; Ol'binskaia, L.I.; Vertkin, A.L.; Shevchenko, O.P.; Karpov, I.A. 1992: Circadian rhythm in the clinical course of cardiovascular diseases. Clinical experience using Norvasc (amlodipine) in the treatment of patients with ischemic heart disease and arterial hypertension Kardiologiia 32(5): 99-112
Glasser, S.P. 2001: Hypertension syndrome and cardiovascular events. High blood pressure is only one risk factor Postgraduate Medicine 110(5): 29-36
Maslova, I.M. 2008: Antihypertensive therapy substantially lowers mortality and rate of cardiovascular events in patients aged 80 years and older Kardiologiia 48(8): 73-74
Fellah, H.; Feki, M.; Taieb, S.H.; Hammami, B.; Boubaker, K.; Lacour, B.; Abdallah, T.B.; Kaabachi, N. 2011: Vitamin A, E, B 12 , and Folic Acid in End-Stage Renal Disease Tunisian Patients: Status and Predictive Value for Overall Mortality and Cardiovascular Events Clinical Laboratory 57(11-12): 939-946
Penesova, A.; Cizmarova, E.; Koska, J. 2006: Early assessment of metabolic situation in young patients with hypertension may prevent subsequent adverse cardiovascular events Bratislavske Lekarske Listy 107(1-2): 41-42
Nordt, T. 2001: Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project Der Internist 42(12): 1705-1707
Guize, L.; Ducimetière, P.; Consoli, S.M.; Kolsky, H.; Raynaud, P.; Walch, J.M.; Paul-Dauphin, A.; Duprat-Lomon, I. 2000: One-year follow-up of a population of patients with angina. Factors influencing mortality and occurrence of cardiovascular events. Results of the ELAN study Archives des Maladies du Coeur et des Vaisseaux 93(3): 227-237
Klomp, C.M.C.; ten Cate, H.; Stehouwer, C.D.A.; Schaper, N.C. 2009: Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events Nederlands Tijdschrift Voor Geneeskunde 153: A109
Iavelov, I.S. 2006: Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials) Kardiologiia 46(3): 75-76